WATCHMAN device

DEVICE2 trials

Sponsors

Boston Scientific Corporation, Hamilton Health Sciences Corporation

Conditions

Atrial FibrillationStrokeStroke, IschemicSystemic Embolism

Phase 3

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

CompletedNCT01182441

Boston Scientific CorporationAtrial Fibrillation, Stroke

Start: 2010-11-30End: 2017-11-30Updated: 2018-07-26

Unknown Phase

The Fourth Left Atrial Appendage Occlusion Study

RecruitingNCT05963698

Hamilton Health Sciences CorporationAtrial Fibrillation, Stroke, Ischemic, Systemic Embolism

Start: 2023-11-30End: 2029-12-01Target: 4000Updated: 2026-09-18

Related Papers

Impact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure.

2022-08-0195 citations

Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.

2022-05-0113 citations

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies.

2019-11-2224 citations

5-Year Outcomes After Left Atrial Appendage Closure

Journal of the American College of Cardiology2017-11-04958 citations

Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin

JACC: Cardiovascular Interventions2015-11-25104 citations